The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | MRD detection with NGS for AML: a new era of diagnostics
Torsten Haferlach
• 19 Jun 2019
Torsten Haferlach, MD, from the Munich Leukemia Laboratory, Munich, Germany, sheds light on a potential of a new era in diagnostics with the use of next-generation sequencing (NGS) for detecting measurable residual disease (MRD) status. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
